Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
AOD-9604
Also known as: Anti-Obesity Drug 9604, HGH Fragment 176-191 (modified)
AOD-9604 is a modified fragment of the C-terminus of human growth hormone (amino acids 176-191) with an added tyrosine at the N-terminal end. Originally developed as an anti-obesity agent, it showed lipolytic activity in preclinical studies but failed to demonstrate significant weight loss in Phase IIb/III clinical trials. It has gained TGA approval in Australia as a food supplement ingredient.
Risk Level
Low RiskDifficulty
Beginner| CAS Number | 221231-10-3 |
| Molecular Formula | C78H123N23O23S2 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Mimics the lipolytic action of HGH by stimulating beta-3 adrenergic receptors and enhancing fat oxidation without affecting IGF-1 levels or inducing hyperglycemia. Does not compete with HGH for receptor binding.
Dosing Research
Typical underground dosing: 250-500 mcg/day subcutaneously, usually administered on an empty stomach. Clinical trials used oral doses up to 1 mg/day. Cycle lengths of 12-20 weeks are commonly reported.
Side Effects & Risks
Generally considered well-tolerated in clinical trials. Reported side effects include injection site reactions, headache, and mild gastrointestinal discomfort. Long-term safety data is limited.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.